$CDLX
Cardlytics, Inc. Stock $cdlx

$cdlx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000166607123000073 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$76.70M	$64.33M
YoY Change	1.72%	-5.3%
Cost Of Revenue	$39.17M	$33.38M
YoY Change	-2.76%	-2.59%
Gross Profit	$37.53M	$30.95M
YoY Change	6.85%	-8.05%
Gross Profit Margin	48.93%	48.11%
Selling, General & Admin	$38.50M	$27.02M
YoY Change	-10.41%	-29.04%
% of Gross Profit	102.57%	87.3%
Research & Development	$14.85M	$11.56M
YoY Change	9.32%	-5.91%
% of Gross Profit	39.56%	37.37%
Depreciation & Amortization	$7.200M	$6.575M
YoY Change	-30.48%	-33.39%
% of Gross Profit	19.18%	21.25%
Operating Expenses	$71.80M	$38.58M
YoY Change	26.97%	-23.39%
Operating Profit	-$34.27M	$12.23M
YoY Change	-71.98%	-65.71%
Interest Expense	$815.0K	$1.381M
YoY Change	-115.05%	-152.75%
% of Operating Profit		11.29%
Other Income/Expense, Net	$815.0K	$1.381M
YoY Change	-115.05%	-152.75%
Pretax Income	-$23.51M	$13.61M
YoY Change	-81.6%	-58.81%
Income Tax	$0.00	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$23.51M	$13.61M
YoY Change	-81.39%	-58.81%
Net Earnings / Revenue	-30.65%	21.15%
Basic Earnings Per Share	-$0.67	$0.41
Diluted Earnings Per Share	-$0.67	$0.40
COMMON SHARES
Basic Shares Outstanding	33.91M shares	33.61M shares
Diluted Shares Outstanding	34.88M shares	36.73M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$92.07M	$139.2M
YoY Change	-41.37%	-33.17%
Cash & Equivalents	$92.07M	$139.2M
Short-Term Investments
Other Short-Term Assets	$7.900M	$8.343M
YoY Change	-18.88%	-6.27%
Inventory
Prepaid Expenses
Receivables	$97.28M	$93.71M
Other Receivables	$4.466M	$5.143M
Total Short-Term Assets	$201.7M	$246.4M
YoY Change	-23.58%	-22.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.911M	$4.755M
YoY Change	-8.21%	-52.01%
Goodwill	$352.7M	$352.7M
YoY Change	-47.02%	-52.82%
Intangibles	$46.56M	$50.01M
YoY Change	-61.53%	-61.01%
Long-Term Investments
YoY Change
Other Assets	$2.493M	$2.621M
YoY Change	-19.74%	-0.64%
Total Long-Term Assets	$431.6M	$438.2M
YoY Change	-47.72%	-51.94%
TOTAL ASSETS
Total Short-Term Assets	$201.7M	$246.4M
Total Long-Term Assets	$431.6M	$438.2M
Total Assets	$633.3M	$684.6M
YoY Change	-41.87%	-44.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.698M	$2.073M
YoY Change	-39.57%	-46.0%
Accrued Expenses	$22.04M	$21.99M
YoY Change	5.14%	50.3%
Deferred Revenue	$3.015M	$2.769M
YoY Change	-35.22%	-11.31%
Short-Term Debt	$30.00M	$0.00
YoY Change
Long-Term Debt Due	$37.00K
YoY Change	0.0%
Total Short-Term Liabilities	$167.9M	$190.8M
YoY Change	-42.79%	-22.67%
LONG-TERM LIABILITIES
Long-Term Debt	$226.8M	$256.4M
YoY Change	0.64%	13.97%
Other Long-Term Liabilities	$2.516M	$5.026M
YoY Change	8885.71%	24.5%
Total Long-Term Liabilities	$229.3M	$261.4M
YoY Change	818792.86%	6375.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$167.9M	$190.8M
Total Long-Term Liabilities	$229.3M	$261.4M
Total Liabilities	$397.2M	$452.3M
YoY Change	-24.39%	-12.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$986.5M	-$963.0M
YoY Change	63.17%	101.34%
Common Stock	$1.220B	$1.191B
YoY Change	4.85%	0.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$236.1M	$232.3M
YoY Change
Total Liabilities & Shareholders Equity	$633.3M	$684.6M
YoY Change	-41.87%	-44.4%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$23.51M	$13.61M
YoY Change	-81.39%	-58.81%
Depreciation, Depletion And Amortization	$7.200M	$6.575M
YoY Change	-30.48%	-33.39%
Cash From Operating Activities	$5.751M	-$10.06M
YoY Change	-186.12%	-48.89%
INVESTING ACTIVITIES
Capital Expenditures	$2.747M	$360.0K
YoY Change	-164.35%	-9.32%
Acquisitions		$0.00
YoY Change		-100.0%
Other Investing Activities	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$2.747M	-$2.802M
YoY Change	-35.65%	-44.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$4.000K
YoY Change		-69.23%
Cash From Financing Activities	-50.08M	$29.98M
YoY Change	25.24%	16373.08%
NET CHANGE
Cash From Operating Activities	5.751M	-$10.06M
Cash From Investing Activities	-2.747M	-$2.802M
Cash From Financing Activities	-50.08M	$29.98M
Net Change In Cash	-47.07M	$17.29M
YoY Change	-7.58%	-168.68%
FREE CASH FLOW
Cash From Operating Activities	$5.751M	-$10.06M
Capital Expenditures	$2.747M	$360.0K
Free Cash Flow	$3.004M	-$10.42M
YoY Change	-224.7%	-48.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001666071
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38386
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	CARDLYTICS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-3039436
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	675 Ponce de Leon Ave. NE, Ste 6000
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Atlanta
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30308
CY2023Q1	dei	City Area Code CityAreaCode	(888)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	792-5802
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2023Q1	dei	Trading Symbol TradingSymbol	CDLX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33908198	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	121905000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	139194000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	80000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	82000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	115609000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	93707000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	4470000	usd
CY2023Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	5143000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7978000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8261000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	250042000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	246387000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5916000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4755000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6571000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7295000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53475000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	50006000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	352721000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	352721000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	19925000	usd
CY2023Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	20811000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2586000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2621000	usd
CY2022Q4	us-gaap	Assets Assets	691236000	usd
CY2023Q1	us-gaap	Assets Assets	684596000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3765000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2073000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10486000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7457000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21335000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21990000	usd
CY2022Q4	cdlx	Financial Institution Share Liability Current FinancialInstitutionShareLiabilityCurrent	48593000	usd
CY2023Q1	cdlx	Financial Institution Share Liability Current FinancialInstitutionShareLiabilityCurrent	38950000	usd
CY2022Q4	cdlx	Customer Incentive Liability CustomerIncentiveLiability	53983000	usd
CY2023Q1	cdlx	Customer Incentive Liability CustomerIncentiveLiability	43354000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1751000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	452276000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	9000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2769000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4910000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4713000	usd
CY2022Q4	cdlx	Contingent Consideration Liability Current ContingentConsiderationLiabilityCurrent	104121000	usd
CY2023Q1	cdlx	Contingent Consideration Liability Current ContingentConsiderationLiabilityCurrent	69537000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	248944000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	190843000	usd
CY2022Q4	us-gaap	Senior Notes SeniorNotes	226047000	usd
CY2023Q1	us-gaap	Senior Notes SeniorNotes	226407000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4306000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4933000	usd
CY2022Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	334000	usd
CY2023Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	93000	usd
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	0	usd
CY2023Q1	us-gaap	Line Of Credit LineOfCredit	30000000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	479631000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	9000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1182568000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1190949000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5598000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4324000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-976570000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-962962000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	211605000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	232320000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	691236000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	684596000	usd
CY2022Q1	us-gaap	Revenues Revenues	67928000	usd
CY2023Q1	us-gaap	Revenues Revenues	64331000	usd
CY2022Q1	cdlx	Financial Institution Share And Other Third Party Costs FinancialInstitutionShareAndOtherThirdPartyCosts	35153000	usd
CY2023Q1	cdlx	Financial Institution Share And Other Third Party Costs FinancialInstitutionShareAndOtherThirdPartyCosts	33384000	usd
CY2022Q1	cdlx	Delivery Costs DeliveryCosts	6533000	usd
CY2023Q1	cdlx	Delivery Costs DeliveryCosts	6424000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	17648000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-8000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13948000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12291000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11564000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20425000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13070000	usd
CY2022Q1	cdlx	Acquisition And Integration Costs Benefit AcquisitionAndIntegrationCostsBenefit	-4599000	usd
CY2023Q1	cdlx	Acquisition And Integration Costs Benefit AcquisitionAndIntegrationCostsBenefit	1723000	usd
CY2022Q1	cdlx	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-65050000	usd
CY2023Q1	cdlx	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-34584000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9871000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6575000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	32272000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	52104000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	35656000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	12227000	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-947000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1671000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1389000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2618000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1381000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	33038000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	13608000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	33038000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	13608000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	33038000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	13608000	usd
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.98
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.41
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.91
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.40
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33741000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33595000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37185000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36727000	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	33038000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	13608000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1367000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1274000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	34405000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	12334000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	211605000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8381000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1274000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	13608000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	232320000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	690700000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	195000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14538000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	11937000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1367000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	33038000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	711670000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	33038000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	13608000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	346000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-246000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9871000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6575000	usd
CY2022Q1	cdlx	Capitalized Contract Cost Amortization Interest Expense CapitalizedContractCostAmortizationInterestExpense	402000	usd
CY2023Q1	cdlx	Capitalized Contract Cost Amortization Interest Expense CapitalizedContractCostAmortizationInterestExpense	407000	usd
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1516000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1235000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	13585000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7968000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-65050000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-34584000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1574000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	905000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-15279000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-21405000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	725000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	369000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-855000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1691000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-11569000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3136000	usd
CY2022Q1	cdlx	Increase Decrease In Financial Institution Share Liability IncreaseDecreaseInFinancialInstitutionShareLiability	-9600000	usd
CY2023Q1	cdlx	Increase Decrease In Financial Institution Share Liability IncreaseDecreaseInFinancialInstitutionShareLiability	-9701000	usd
CY2022Q1	cdlx	Increase Decrease In Consumer Incentive Liability IncreaseDecreaseInConsumerIncentiveLiability	-7503000	usd
CY2023Q1	cdlx	Increase Decrease In Consumer Incentive Liability IncreaseDecreaseInConsumerIncentiveLiability	-10630000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19691000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10064000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	397000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	360000	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	49000	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2022Q1	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	2314000	usd
CY2023Q1	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	2442000	usd
CY2022Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2274000	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5034000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2802000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	30000000	usd
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	13000	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	195000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	15000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	182000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29981000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-634000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	176000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-25177000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17291000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	233562000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	121985000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	208385000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139276000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	208293000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	139194000	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	92000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	82000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	208385000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	139276000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	1169000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1268000	usd
CY2022Q1	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	11937000	usd
CY2023Q1	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	0	usd
CY2022Q1	cdlx	Property And Equipment Incurred But Not Yet Paid PropertyAndEquipmentIncurredButNotYetPaid	29000	usd
CY2023Q1	cdlx	Property And Equipment Incurred But Not Yet Paid PropertyAndEquipmentIncurredButNotYetPaid	0	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Significant items subject to such estimates and assumptions include revenue recognition, internal-use software development costs, stock-based compensation, allowance for doubtful accounts, valuation of acquired intangible assets, valuation of contingent consideration for Bridg, goodwill impairment, income tax including valuation allowance and contingencies. We base our estimates on historical experience and on assumptions that we believe are reasonable. Changes in facts or circumstances may cause us to change our assumptions and estimates in future periods and it is possible that actual results could differ from our current or revised future estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Macroeconomic Considerations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unfavorable conditions in the economy both in the United States and abroad may negatively affect the growth of our business and our results of operations. For example, macroeconomic events, including the COVID-19 pandemic, rising inflation, the U.S. Federal Reserve raising interest rates, disruptions in access to bank deposits or lending commitments due to bank failures and the Russia-Ukraine war have led to economic uncertainty globally. Historically, during periods of economic uncertainty and downturns, businesses may slow spending on advertising, which may impact our business and our customers’ businesses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect of macroeconomic conditions may not be fully reflected in our results of operations until future periods. If, however, economic uncertainty increases or the global economy worsens, our business, financial condition and results of operations may be harmed. For further discussion of the potential impacts of macroeconomic events on our business, financial condition and operating results, see the section titled “Risk Factors.”</span></div>
CY2022Q1	cdlx	Acquisition And Integration Costs Benefit AcquisitionAndIntegrationCostsBenefit	-4600000	usd
CY2023Q1	cdlx	Acquisition And Integration Costs Benefit AcquisitionAndIntegrationCostsBenefit	1700000	usd
CY2022Q1	us-gaap	Distribution Made To Limited Partner Cash Distributions Paid DistributionMadeToLimitedPartnerCashDistributionsPaid	24000	usd
CY2022Q1	us-gaap	Proceeds From Limited Partnership Investments ProceedsFromLimitedPartnershipInvestments	61000	usd
CY2023Q1	us-gaap	Goodwill Gross GoodwillGross	748963000	usd
CY2023Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	396242000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	352721000	usd
CY2022Q2	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	83100000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	313100000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	92300000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	42384000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	49916000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7100000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3500000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	154500000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	44732000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	53373000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	10278000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	13269000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	11808000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	9673000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4888000	usd
CY2023Q1	cdlx	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	0	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	49916000	usd
CY2022Q1	cdlx	Consumer Incentives Expense ConsumerIncentivesExpense	30300000	usd
CY2023Q1	cdlx	Consumer Incentives Expense ConsumerIncentivesExpense	31300000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	63983000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59030000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	28000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	391000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2084000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2860000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	15600000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	14100000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	0	usd
CY2023Q1	us-gaap	Line Of Credit LineOfCredit	30000000	usd
CY2020Q3	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	226047000	usd
CY2023Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	226407000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	226047000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	256407000	usd
CY2022Q1	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	700000	usd
CY2023Q1	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	100000	usd
CY2020Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	230000000	usd
CY2020Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0100
CY2020Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	222700000	usd
CY2020Q3	cdlx	Adjustments To Additional Paid In Capital Issuance Of Capped Calls AdjustmentsToAdditionalPaidInCapitalIssuanceOfCappedCalls	26500000	usd
CY2020Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0100
CY2020Q3	us-gaap	Debt Instrument Convertible Threshold Consecutive Trading Days1 DebtInstrumentConvertibleThresholdConsecutiveTradingDays1	10000	numberofdays
CY2020Q3	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.98
CY2020Q3	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	11.7457
CY2020Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	85140
CY2020Q3	cdlx	Debt Instrument Convertible Redemption Period Days Before Maturity Date DebtInstrumentConvertibleRedemptionPeriodDaysBeforeMaturityDate	P36D
CY2020Q3	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1
CY2023Q1	cdlx	Debt Instrument Convertible Threshold Principal Outstanding Amount For Partial Redemption DebtInstrumentConvertibleThresholdPrincipalOutstandingAmountForPartialRedemption	75000000	usd
CY2020Q3	cdlx	Debt Instrument Required Compliance Period Period After Written Notice DebtInstrumentRequiredCompliancePeriodPeriodAfterWrittenNotice	P60D
CY2020Q3	cdlx	Debt Instrument Convertible Percentage Of Holders To Require Written Notice Of Noncompliance DebtInstrumentConvertiblePercentageOfHoldersToRequireWrittenNoticeOfNoncompliance	0.25
CY2020Q3	cdlx	Debt Instrument Convertible Redemption Requirement Amount Of Other Debt Called Due DebtInstrumentConvertibleRedemptionRequirementAmountOfOtherDebtCalledDue	35000000	usd
CY2020Q3	cdlx	Debt Instrument Convertible Percentage Of Holders To Require Written Notice Of Noncompliance DebtInstrumentConvertiblePercentageOfHoldersToRequireWrittenNoticeOfNoncompliance	0.25
CY2023Q1	cdlx	Debt Instrument Convertible Percentage Of Holders To Require Written Notice Of Noncompliance DebtInstrumentConvertiblePercentageOfHoldersToRequireWrittenNoticeOfNoncompliance	0.25
CY2023Q1	cdlx	Debt Instrument Convertible Covenant Noncompliance Period Of Additional Interest DebtInstrumentConvertibleCovenantNoncompliancePeriodOfAdditionalInterest	P365D
CY2023Q1	cdlx	Debt Instrument Convertible Liability Component Discount Rate DebtInstrumentConvertibleLiabilityComponentDiscountRate	0.0650
CY2022Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	575000	usd
CY2023Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	575000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	365000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	365000	usd
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	940000	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	940000	usd
CY2022Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0164
CY2023Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0164
CY2020Q3	cdlx	Adjustments To Additional Paid In Capital Issuance Of Capped Calls AdjustmentsToAdditionalPaidInCapitalIssuanceOfCappedCalls	26500000	usd
CY2020Q3	us-gaap	Option Indexed To Issuers Equity Strike Price1 OptionIndexedToIssuersEquityStrikePrice1	85.14
CY2020Q3	cdlx	Option Indexed To Issuers Equity Cap Price OptionIndexedToIssuersEquityCapPrice	128.51
CY2023Q1	cdlx	Line Of Credit Facility Maximum Borrowing Capacity Percentage Of Eligible Accounts Receivable LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable	0.50
CY2023Q1	us-gaap	Line Of Credit LineOfCredit	30000000	usd
CY2023Q1	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	5500000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	405830	shares
CY2023Q1	cdlx	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Annual Percentage Increase ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAnnualPercentageIncrease	0.05
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1673858	shares
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13585000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7968000	usd
CY2022Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	200000	usd
CY2023Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	400000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5887000	shares
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	396200000	usd
CY2021Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	232295000	usd
CY2022Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	104121000	usd
CY2022Q1	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-65050000	usd
CY2023Q1	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-34584000	usd
CY2022Q1	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	167245000	usd
CY2023Q1	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	69537000	usd
CY2020Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	230000000	usd
CY2020Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0100
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	33978000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	14548000	usd
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33741000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33595000	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2701000	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2701000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37185000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36727000	shares
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.91
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.40
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2022Q1	cdlx	Adjusted Contribution AdjustedContribution	32775000	usd
CY2023Q1	cdlx	Adjusted Contribution AdjustedContribution	30947000	usd
CY2022Q1	cdlx	Financial Institution Share And Oth0er Third Party Costs Excluding Non Cash Equity Expense And Deferred Implementation Costs FinancialInstitutionShareAndOth0erThirdPartyCostsExcludingNonCashEquityExpenseAndDeferredImplementationCosts	35153000	usd
CY2023Q1	cdlx	Financial Institution Share And Oth0er Third Party Costs Excluding Non Cash Equity Expense And Deferred Implementation Costs FinancialInstitutionShareAndOth0erThirdPartyCostsExcludingNonCashEquityExpenseAndDeferredImplementationCosts	33384000	usd
CY2022Q1	us-gaap	Revenues Revenues	67928000	usd
CY2023Q1	us-gaap	Revenues Revenues	64331000	usd
CY2022Q1	cdlx	Adjusted Contribution AdjustedContribution	32775000	usd
CY2023Q1	cdlx	Adjusted Contribution AdjustedContribution	30947000	usd
CY2022Q1	cdlx	Delivery Costs DeliveryCosts	6533000	usd
CY2023Q1	cdlx	Delivery Costs DeliveryCosts	6424000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	17648000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13948000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12291000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11564000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20425000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13070000	usd
CY2022Q1	cdlx	Acquisition And Integration Costs Benefit AcquisitionAndIntegrationCostsBenefit	-4599000	usd
CY2023Q1	cdlx	Acquisition And Integration Costs Benefit AcquisitionAndIntegrationCostsBenefit	1723000	usd
CY2022Q1	cdlx	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-65050000	usd
CY2023Q1	cdlx	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-34584000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9871000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6575000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2618000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1381000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	33038000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	13608000	usd
CY2022Q1	us-gaap	Revenues Revenues	67928000	usd
CY2023Q1	us-gaap	Revenues Revenues	64331000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5916000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4755000	usd

Files In Submission

Name	View Source	Status
cdlx-20230331_def.xml	Edgar Link	unprocessable
cdlx-20230331_lab.xml	Edgar Link	unprocessable
0001666071-23-000073-index-headers.html	Edgar Link	pending
0001666071-23-000073-index.html	Edgar Link	pending
0001666071-23-000073.txt	Edgar Link	pending
0001666071-23-000073-xbrl.zip	Edgar Link	pending
cdlx-20230331.htm	Edgar Link	pending
cdlx-20230331.xsd	Edgar Link	pending
cdlx-20230331_g1.jpg	Edgar Link	pending
cdlx-20230331_cal.xml	Edgar Link	unprocessable
cdlx_form10-qx2023q1xex103.htm	Edgar Link	pending
cdlx_form10-qx2023q1xex104.htm	Edgar Link	pending
cdlx_form10-qx2023q1xex105.htm	Edgar Link	pending
cdlx_form10-qx2023q1xex311.htm	Edgar Link	pending
cdlx_form10-qx2023q1xex312.htm	Edgar Link	pending
cdlx_form10-qx2023q1xex321.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
cdlx-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cdlx-20230331_htm.xml	Edgar Link	completed
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDLX
Cardlytics, Inc. Stock $cdlx

2023 Q2 Form 10-Q Financial Statement

#000166607123000073 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDLX Cardlytics, Inc. Stock $cdlx

2023 Q2 Form 10-Q Financial Statement

#000166607123000073 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDLX
Cardlytics, Inc. Stock $cdlx